Communiqués AstraZeneca PLC NYSE

Actions

AZN

US0463531089

Produits pharmaceutiques

Marché Fermé - NYSE Autres places de cotation 22:00:02 12/06/2026			Varia. 5j.	Varia. 1 janv.
178,75 ^USD	-1,94%		-3,87%	+94,44%

12/06	AstraZeneca : la FDA approuve l'association Truqap dans le traitement du cancer de la prostate	AN
12/06	AstraZeneca : la FDA approuve la combinaison Truqap pour le traitement du cancer de la prostate avec déficit en PTEN	MT

Communiqués

00:45	TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	BU
12/06	AstraZeneca : Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer	PU
08/06	AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio	PU
07/06	CEO of AstraZeneca: “AI is fundamentally changing the way we develop medicines”	AQ
02/06	Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026	AQ
02/06	AstraZeneca - Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial	AQ
02/06	Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial	BU
02/06	AstraZeneca : Presentation (ASCO2026 Presentation 20260601)	PU
02/06	AstraZeneca : Biographies (ASCO2026 biographies 20260601)	PU
01/06	IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial	BU
29/05	AstraZeneca : CARES Phase III clinical programme did not meet primary endpoint in overall light chain amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa light chain amyloidosis	PU
29/05	IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer	BU
28/05	AstraZeneca : Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer.	PU
22/05	DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates	BU
22/05	AstraZeneca : Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates	PU
22/05	AstraZeneca : Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours	PU
22/05	AstraZeneca : Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer	PU
22/05	AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026	BU
20/05	Lund University: New study: BMI alone does not fully capture health risks linked to obesity	AQ
18/05	BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension	BU
18/05	AstraZeneca : Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension	PU
18/05	AstraZeneca : Baxfendy approved in the US for hypertension	PU
16/05	ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer	BU
16/05	AstraZeneca : Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer	PU
14/05	Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial	BU